Sugi Predict

Sugi Predict / Compounds / SCHEMBL1021685

SCHEMBL1021685

SCHEMBL1021685

CC1CN(C(=O)O)CC(C)N1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 16/20 0.38
▸ CHRNA3 P32297 16/20 0.38
▸ CHRNA4 P43681 16/20 0.38
▸ CHRNB3 Q05901 11/20 0.38
▸ CHRNA6 Q15825 11/20 0.38
▸ CHRNB4 P30926 5/20 0.32
▸ TSHR P16473 2/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ OPRD1 P41143 1/20 0.32
▸ BIRC2 Q13490 1/20 0.32
▸ CHRNA7 P36544 4/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21543557 1.00 CHRNB2 (0.38) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL29016247 1.00 CHRNB2 (0.38) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL15819325 1.00 CHRNB2 (0.38) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL1714522 1.00 CHRNB2 (0.38) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL28988671 1.00 CHRNB2 (0.38) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL28449710 0.85 CHRNB2 (0.32) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL899597 0.82 CHRNB2 (0.31) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL19154968 0.82 CHRNB2 (0.35) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL24802897 0.80 CHRNB2 (0.60) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL13435466 0.80 CHRNB2 (0.60) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765327-A4 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2009-06-17 — — EP claimed
EP-1962852-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-09-03 — — EP claimed
WO-2007078839-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-07-12 — — WO claimed
EP-1765327-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2007-03-28 — — EP claimed
WO-2006009726-A2 SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES CYTOKINETICS, INC. (US) 2006-01-26 — — WO claimed
EP-4747258-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics, Inc. (US) 2026-05-27 — — EP disclosed
US-12465643-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-11-11 — — US disclosed
US-20250319187-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-10-16 — — US disclosed
US-12409225-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-09 — — US disclosed
US-12403196-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-02 — — US disclosed
US-20250255964-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-08-14 — — US disclosed
US-20250242029-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2025-07-31 — — US disclosed
US-20030013721-A1 Novel piperidine and piperazine derivatives ASTRAZENECA AB (SE) 2003-01-16 — — US disclosed
US-6495549-B1 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE PFIZER INC 2002-12-17 — — US disclosed
EP-1098894-B1 FKBP INHIBITORS PFIZER LTD (GB) 2002-10-02 — — EP disclosed
EP-1242427-A1 NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AstraZeneca AB (SE) 2002-09-25 — — EP disclosed
WO-2001046200-A1 NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES ASTRAZENECA AB (SE) 2001-06-28 — — WO disclosed
EP-1098894-A1 FKBP INHIBITORS Pfizer Limited (GB) 2001-05-16 — — EP disclosed
US-6166011-A FKBP inhibitors PFIZER INC (US) 2000-12-26 — — US disclosed
WO-2000005231-A1 FKBP INHIBITORS PFIZER LIMITED (GB) 2000-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319187-A1 RAS INHIBITORS KRAS, NRAS, HRAS CHRNB2 4838/4885CHRNA3 4860/4885CHRNA4 4878/4885
US-20030013721-A1 Novel piperidine and piperazine derivatives IL5, VIP, EP300 CHRNB2 4132/4885CHRNA3 3571/4885CHRNA4 3117/4885
US-20250255964-A1 RAS INHIBITORS KRAS, NRAS, HRAS CHRNB2 4838/4885CHRNA3 4860/4885CHRNA4 4878/4885
US-12403196-B2 Ras inhibitors KRAS, NRAS, HRAS CHRNB2 4838/4885CHRNA3 4860/4885CHRNA4 4878/4885
US-12465643-B2 Ras inhibitors KRAS, NRAS, HRAS CHRNB2 4838/4885CHRNA3 4860/4885CHRNA4 4878/4885
US-20250242029-A1 RAS INHIBITORS KRAS, NRAS, HRAS CHRNB2 4838/4885CHRNA3 4860/4885CHRNA4 4878/4885
US-12409225-B2 Ras inhibitors KRAS, NRAS, HRAS CHRNB2 4838/4885CHRNA3 4860/4885CHRNA4 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.